Answers are grounded in this paper and cite their sources.
Matrix metalloproteinases (MMPs) catalyze extracellular matrix degradation. Control of their activity is a promising target for therapy of diseases characterized by abnormal connective tissue turnover. MMPs are expressed as latent proenzymes that are activated by proteolytic cleavage that triggers a conformational change in the propeptide (cysteine switch). The structure of proMMP-2 reveals how the propeptide shields the catalytic cleft and that the cysteine switch may operate through cleavage of loops essential for propeptide stability.
No takes yet. Share an insight, caveat, or question.
Morgunova et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: